The injection is the first treatment for ulcerative colitis that targets p19, a specific protein subunit that contributes to ulcerative colitis-related inflammation, according to an Oct. 26 news release from the drugmaker.
Omvoh will be available in the United States in the coming weeks. The drug was approved in Japan and the European Union earlier this year, according to the release.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
